NeoImmuneTech Inc (KOSDAQ: 950220), a US-based clinical-stage T cell-focused biopharmaceutical company, announced on Tuesday that it has named Luke Oh, PhD as its new president and chief executive officer (CEO).
Dr Oh is to succeed Dr Se Hwan Yang, PhD. In the new role, Dr. Oh will head the company from its Rockville headquarters and oversee all of the company's Korea operations.
With more than six years of regulatory experience at the US FDA, Dr Oh has also served as vice-president in charge of Regulatory Development at Samsung Bioepis, senior staff fellow at the US FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and in various roles in research and development for leading organisations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences and Vertex Pharmaceuticals.
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323
Q32 Bio added to Russell 3000 Index
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Triveni Bio appoints new chief medical officer, announces key program updates
UCB presents bimekizumab two-year data for axial spondyloarthritis and psoriatic arthritis
GIE Medical commences patient enrolment for Chronic Benign Stricture - Bowel (PATENT-B) study
Sen-Jam Pharmaceutical signs third strategic partnership with KVK-Tech
IASO Biotechnology's BCMA CAR-T (Equecabtagene Autoleucel) IND application receives FDA approval